Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder.

Altamura AC, Dell'osso B, D'Urso N, Russo M, Fumagalli S, Mundo E.

CNS Spectr. 2008 May;13(5):415-22.

PMID:
18496479
2.
3.

Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.

Bereza BG, Machado M, Einarson TR.

Clin Ther. 2009 Jun;31(6):1279-308. doi: 10.1016/j.clinthera.2009.06.004. Review.

PMID:
19695395
4.

Duration of untreated psychosis and duration of untreated illness: new vistas.

Dell'osso B, Altamura AC.

CNS Spectr. 2010 Apr;15(4):238-46. Review.

PMID:
20414173
5.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
6.

A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder.

Allgulander C, Nutt D, Detke M, Erickson J, Spann M, Walker D, Ball S, Russell J.

J Psychopharmacol. 2008 Jun;22(4):417-25. doi: 10.1177/0269881108091588.

PMID:
18635722
7.

Generalized anxiety disorder: raising the expectations of treatment.

Allgulander C, Sheehan DV.

Psychopharmacol Bull. 2002 Summer;36 Suppl 2:68-78. Review.

PMID:
17450651
8.

Overview of generalized anxiety disorder: epidemiology, presentation, and course.

Weisberg RB.

J Clin Psychiatry. 2009;70 Suppl 2:4-9. Review.

9.

Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission.

Pollack MH.

J Clin Psychiatry. 2001;62 Suppl 19:20-5. Review.

10.

What is generalized anxiety disorder?

Rickels K, Rynn MA.

J Clin Psychiatry. 2001;62 Suppl 11:4-12; discussion 13-4. Review.

11.

[Pharmacological treatment of generalized anxiety disorders: rationale and limitations].

Boulenger JP, Capdevielle D.

Encephale. 2007 Jan-Feb;33(1):84-94. Review. French.

PMID:
17457298
12.

Diagnosis and management of generalized anxiety disorder.

Roerig JL.

J Am Pharm Assoc (Wash). 1999 Nov-Dec;39(6):811-21; quiz 877-9. Review.

PMID:
10609447
13.

First-line pharmacotherapy approaches for generalized anxiety disorder.

Davidson JR.

J Clin Psychiatry. 2009;70 Suppl 2:25-31. Review.

14.

Current considerations in the treatment of generalized anxiety disorder.

Katzman MA.

CNS Drugs. 2009;23(2):103-20. doi: 10.2165/00023210-200923020-00002. Review.

PMID:
19173371
15.

Generalized anxiety disorder: acute and chronic treatment.

Rynn MA, Brawman-Mintzer O.

CNS Spectr. 2004 Oct;9(10):716-23. Review.

PMID:
15448583
16.

[Antidepressants and their onset of action: a major clinical, methodological and pronostical issue].

Gourion D.

Encephale. 2008 Jan;34(1):73-81. doi: 10.1016/j.encep.2007.12.001. Epub 2008 Feb 5. Review. French.

PMID:
18514154
17.

Defining response and remission in anxiety disorders: toward an integrated approach.

Bandelow B.

CNS Spectr. 2006 Oct;11(10 Suppl 12):21-8. Review.

PMID:
17008827
18.

[Understanding the role of the duration of untreated illness in psychiatric disorders: a narrative review].

Altamura AC, Camuri G, Dell'Osso B.

Riv Psichiatr. 2010 Jul-Aug;45(4):197-208. Review. Italian.

PMID:
20942365
19.

New insights into the diagnosis and pharmacologic management of generalized anxiety disorder.

Ninan PT.

Psychopharmacol Bull. 2002 Spring;36(2):105-22. Review.

PMID:
12397844
20.

Duration of untreated illness and duration of illness in anxiety disorders: assessment and influence on outcome.

Altamura AC, Camuri G, Dell'Osso B.

Mod Trends Pharmacopsychiatry. 2013;29:111-8. doi: 10.1159/000351950. Epub 2013 Sep 20. Review.

PMID:
25225021

Supplemental Content

Support Center